Search

Your search keyword '"Nielsen, Ulrik"' showing total 151 results

Search Constraints

Start Over You searched for: Author "Nielsen, Ulrik" Remove constraint Author: "Nielsen, Ulrik" Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
151 results on '"Nielsen, Ulrik"'

Search Results

4. Estimating waves via measured ship responses

26. Supplementary Table 4 from MM-141, an IGF-IR– and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors

27. Supplementary Materials and Methods from MM-141, an IGF-IR– and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors

28. Supplementary Tables S5, S6, S7, S8 from Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic

29. Supplementary Figures 1-4, Table 1 from Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3

31. Supplementary Figure Legends from MM-141, an IGF-IR– and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors

33. Data from MM-141, an IGF-IR– and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors

34. Supplementary Table S1 from Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic

37. Supplementary Figures S1-S6 from Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302)

41. Supplementary Tables S2, S3, S4 from Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic

44. Supplementary Figures 1 through 10 and Supplementary Tables 1 through 3 from MM-141, an IGF-IR– and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors

45. Supplementary Tables S1-S3 from Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302)

46. Supplementary Methods, Figures S1-S11, and Table Legends from Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic

47. Supplementary Materials and Methods from Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302)

Catalog

Books, media, physical & digital resources